LifeVantage Corporation (LFVN)

Market Cap	80.14M
Revenue (ttm)	228.88M
Net Income (ttm)	10.13M
Shares Out	12.70M
EPS (ttm)	0.78
PE Ratio	8.10
Forward PE	5.68
Dividend	$0.18 (2.85%)
Ex-Dividend Date	Dec 1, 2025

Volume	102,303
Open	6.40
Previous Close	6.40
Day's Range	6.28 - 6.68
52-Week Range	5.98 - 27.38
Beta	0.31
Analysts	Strong Buy
Price Target	30.50 (+383.36%)
Earnings Date	Nov 4, 2025

About LFVN

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre- and pro-biotics and skin and hair care products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fati...

• Industry: Packaged Foods
• Sector: Consumer Staples
• CEO: Steven Fife
• Employees: 238
• Stock Exchange: NASDAQ
• Ticker Symbol: LFVN
• Website: https://www.lifevantage.com

Financial Performance

In 2025, LifeVantage's revenue was $228.53 million, an increase of 14.17% compared to the previous year's $200.16 million. Earnings were $9.81 million, an increase of 233.84%.

Analyst Summary

According to 2 analysts, the average rating for LFVN stock is "Strong Buy." The 12-month stock price target is $30.5, which is an increase of 383.36% from the latest price.

Price Target

$30.5

(383.36% upside)

Analyst Consensus: Strong Buy